Flag of the European Union EU Clinical Trials Register Help

Clinical trials for abbvie

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    554 result(s) found for: abbvie. Displaying page 4 of 28.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-003123-32 Sponsor Protocol Number: M16-006 Start Date*: 2017-09-15
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10013099 Disease Crohns LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) DE (Completed) GB (GB - no longer in EU/EEA) PT (Completed) IE (Completed) BG (Completed) AT (Completed) LV (Completed) PL (Completed) BE (Completed) NL (Completed) EE (Completed) SE (Completed) ES (Completed) GR (Completed) NO (Completed) LT (Completed) HR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2016-003190-17 Sponsor Protocol Number: M15-991 Start Date*: 2017-08-23
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Who Fail...
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10013099 Disease Crohns LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DK (Completed) CZ (Completed) DE (Completed) GB (GB - no longer in EU/EEA) PT (Completed) IE (Completed) BG (Completed) AT (Completed) LV (Completed) PL (Completed) NL (Completed) EE (Completed) LT (Completed) ES (Completed) GR (Completed) BE (Completed) FR (Completed) HR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-001590-16 Sponsor Protocol Number: M15-563 Start Date*: 2019-07-02
    Sponsor Name:AbbVie Deutschland
    Full Title: An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)
    Medical condition: Progressive Supranuclear Palsy (PSP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10036813 Progressive supranuclear palsy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002700-78 Sponsor Protocol Number: DDD16RITONAVIR Start Date*: 2016-10-28
    Sponsor Name:KU Leuven - Drug Delivery and Disposition
    Full Title: Supersaturation and precipitation of ritonavir in the gastrointestinal tract of healthy volunteers
    Medical condition: Healthy human volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002012-33 Sponsor Protocol Number: M15-461 Start Date*: 2015-09-24
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infec...
    Medical condition: Chronic Hepatitis C infection
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-004182-60 Sponsor Protocol Number: M16-127 Start Date*: 2017-05-08
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Open-Label, Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Renally-Impaired Adults with Chronic Hepatitis C Virus Genotype 1 – 6 Infection
    Medical condition: HCV
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000074171 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) DE (Completed) PL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000268-26 Sponsor Protocol Number: M15-570 Start Date*: 2019-06-25
    Sponsor Name:AbbVie Deutschland
    Full Title: An Extension Study of ABBV-8E12 in Early Alzheimer's Disease
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) FI (Completed) BE (Completed) DK (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004932-12 Sponsor Protocol Number: M16-766 Start Date*: 2018-10-02
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects with Moderate to Severe Plaque Psoriasis who are C...
    Medical condition: Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) NL (Completed) ES (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002610-13 Sponsor Protocol Number: M11-612 Start Date*: 2013-12-06
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Open-Label, Multicenter Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 with Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hem...
    Medical condition: - Stage 5 chronic kidney disease - Secondary to hyperparathyroidism
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PT (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-005577-20 Sponsor Protocol Number: M14-730 Start Date*: 2016-07-12
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus (HCV) Genotypes 1-6 Infection and Human Immunodeficiency Virus-1 (HIV...
    Medical condition: Hepatitis C Virus Infection Human Immunodeficiency Virus Infection Chronic Hepatitis C Compensated Cirrhosis and Non-cirrhotics
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-002272-24 Sponsor Protocol Number: M13-594 Start Date*: 2016-01-26
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered with Daclatasvir in Adults with Chronic Hepatitis C Vi...
    Medical condition: Chronic HCV Genotype 3 Infection
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003686-26 Sponsor Protocol Number: M16-300 Start Date*: 2017-08-28
    Sponsor Name:AbbVie Stemcentrx LLC
    Full Title: A Phase 1/2 Study on the Safety of Rovalpituzumab Tesirine Administered in Combination with Nivolumab or Nivolumab and Ipilimumab for Adults with Extensive-Stage Small Cell Lung Cancer
    Medical condition: Extensive-Stage Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005161-23 Sponsor Protocol Number: M15-574 Start Date*: 2016-08-30
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 4, Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction with Surgery in Subjects with Moderate to Severe Hidrad...
    Medical condition: Hidradenitis Suppurativa (also known as Acne inversa)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) NL (Completed) GB (Completed) DE (Completed) IE (Completed) PT (Completed) GR (Completed) BE (Completed) ES (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001097-15 Sponsor Protocol Number: M15-889 Start Date*: 2016-09-28
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Impact of Venetoclax on the Quality of Life of Relapsed/Refractory Subjects with Chronic Lymphocytic Leukemia (CLL) (Venice II)
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-000439-14 Sponsor Protocol Number: M13-833 Start Date*: 2018-03-08
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies
    Medical condition: In Part 1 patients with any relapsed or refractory tumor will be eligible to enroll. During Part 2 patients with the following malignancies: acute lymphoblastic leukemia (ALL), acute myeloid leu...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-000431-14 Sponsor Protocol Number: M16-098 Start Date*: 2017-11-13
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects with Active Ankylosing Spondylitis
    Medical condition: Active Ankylosing Spondylitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DK (Completed) DE (Completed) FI (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) ES (Completed) PT (Completed) NL (Completed) BE (Completed) HU (Completed) PL (Completed) SE (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-005126-37 Sponsor Protocol Number: M16-047 Start Date*: 2018-10-30
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic De...
    Medical condition: Moderate and Severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Trial now transitioned) SE (Trial now transitioned) SK (Trial now transitioned) CZ (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) AT (Trial now transitioned) GR (Trial now transitioned) NO (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003759-23 Sponsor Protocol Number: M14-327 Start Date*: 2016-11-04
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects with Crohn's Di...
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10013099 Disease Crohns LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) NL (Trial now transitioned) SK (Trial now transitioned) CZ (Completed) BE (Completed) ES (Ongoing) FR (Trial now transitioned) HU (Completed) NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001398-17 Sponsor Protocol Number: M16-109 Start Date*: 2017-10-04
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis
    Medical condition: Myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) HU (Completed) BE (Completed) IT (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-005848-21 Sponsor Protocol Number: M11-352 Start Date*: 2013-12-18
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy SONAR: Stud...
    Medical condition: Diabetic Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) BE (Prematurely Ended) GB (Completed) IE (Completed) PT (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended) GR (Completed) SK (Prematurely Ended) FI (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 06:50:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA